title: A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group.
abstract: OBJECTIVE
  To determine whether adequate concentrations of a new formulation of tobramycin could be delivered to the lower respiratory tract of patients with cystic fibrosis (CF) using a jet nebulizer delivery system.
  
  
  METHODS
  A multicenter, open-label, randomized, crossover study.
  
  
  METHODS
  Ten tertiary care, university-affiliated, teaching hospitals in the United States.
  
  
  METHODS
  Sixty-eight patients recruited from 10 CF Foundation centers and who were at least 8 years of age, had a diagnosis of CF, and expectorated daily sputum. No control subjects enrolled.
  
  
  METHODS
  Each patient received one administration of aerosolized tobramycin from each of the three nebulizer systems in random order. Each administration was separated by a minimum of 48 h. The two jet nebulizer systems tested were the Sidestream (Medic-Aid; Sussex, UK), and the Pari LC (Pari Respiratory Equipment; Richmond, Va), with a DeVilbiss Pulmoaide compressor (DeVilbiss Health Care; Somerset, Pa), both administering 300 mg tobramycin in 5 mL of 1/4 normal saline solution (NS). Patients were also administered 600 mg tobramycin in 30 mL of 1/2 NS with the UltraNeb 99/100 (DeVilbiss).
  
  
  METHODS
  Sputum and serum tobramycin concentration and pulmonary function were monitored. An adequate peak sputum tobramycin concentration was defined as > 128 microg/g sputum at any of three time points (10, 60, or 120 min) after completion of treatments.
  
  
  RESULTS
  The peak tobramycin concentrations in expectorated sputum were 687+/-663 microg/g (mean+/-SD) with the Pari LC and 489+/-402 microg/g with the Sidestream. Adequate peak sputum tobramycin concentration was achieved in 93% of the patients with the Sidestream, and in 87% of the patients with the Pari LC. Peak sputum concentrations were found to be substantially higher when patients received tobramycin administered with the UltraNeb 99/100, 1,498+/-1,331 microg/g with 30% of patients having levels exceeding 2,000 microg/g. Serum tobramycin concentrations were < or = 4 microg/mL for all patients following administration with each nebulizer.
  
  
  CONCLUSIONS
  Adequately high sputum tobramycin concentrations were documented in sputum in > 85% of patients following the administration of 300 mg/5 mL formulation of tobramycin aerosolized by the two jet nebulizer delivery systems, Sidestream and Pari LC. The single tobramycin administration delivered by these two systems is well-tolerated.
authors.affiliation: Oregon Health Sciences University, Portland, USA.
authors.forename: J
authors.initials: J
authors.lastname: Eisenberg
authors.forename: M
authors.initials: M
authors.lastname: Pepe
authors.forename: J
authors.initials: J
authors.lastname: Williams-Warren
authors.forename: M
authors.initials: M
authors.lastname: Vasiliev
authors.forename: A B
authors.initials: AB
authors.lastname: Montgomery
authors.forename: A L
authors.initials: AL
authors.lastname: Smith
authors.forename: B W
authors.initials: BW
authors.lastname: Ramsey
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D018592:Cross-Over Studies; D003550:Cystic Fibrosis / Q000188:drug therapy* / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D009330:Nebulizers and Vaporizers; D013183:Sputum / Q000737:chemistry*; D014031:Tobramycin / Q000008:administration & dosage* / Q000032:analysis* / Q000493:pharmacokinetics; D014465:Ultrasonics
chemical_list: D014031:Tobramycin